ALLMedicine™ Pediatric HIV Infection Center
Research & Reviews 97 results
https://emedicine.medscape.com/article/1133746-overview
Mar 20th, 2023 - Overview Cutaneous manifestations of human immunodeficiency virus (HIV) disease may result from HIV infection itself or from opportunistic disorders secondary to the decline in immunocompetence from the disease. [1] Cutaneous disorders may be the ...
http://emedicine.medscape.com/article/1133746-overview
Mar 20th, 2023 - Overview Cutaneous manifestations of human immunodeficiency virus (HIV) disease may result from HIV infection itself or from opportunistic disorders secondary to the decline in immunocompetence from the disease. [1] Cutaneous disorders may be the ...
https://emedicine.medscape.com/article/1133746-print
Mar 20th, 2023 - Cutaneous manifestations of human immunodeficiency virus (HIV) disease may result from HIV infection itself or from opportunistic disorders secondary to the decline in immunocompetence from the disease.[1] Cutaneous disorders may be the initial si...
https://clinicaltrials.gov/ct2/show/NCT01656564
Mar 9th, 2023 - Background: Antiretroviral therapy (ART) has altered the natural history of HIV disease in children. Long-term survivors of pediatric HIV infection offer a tremendous opportunity to understand the effects of HIV and ART health outcomes. A thorough...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951512
BMC Neuroscience; Nwosu EC, Holmes MJ et. al.
Feb 25th, 2023 - Life-long early ART (started before age 2 years), often with periods of treatment interruption, is now the standard of care in pediatric HIV infection. Although cross-sectional studies have investigated HIV-related differences in cortical morpholo...
Clinicaltrials.gov 13 results
https://clinicaltrials.gov/ct2/show/NCT01656564
Mar 9th, 2023 - Background: Antiretroviral therapy (ART) has altered the natural history of HIV disease in children. Long-term survivors of pediatric HIV infection offer a tremendous opportunity to understand the effects of HIV and ART health outcomes. A thorough...
https://clinicaltrials.gov/ct2/show/NCT03425136
May 17th, 2022 - Despite significant increases in global health investment and the availability of low-cost, efficacious interventions designed to prevent mother to child HIV transmission (PMTCT) in low and middle income countries with high HIV burden, the transla...
https://clinicaltrials.gov/ct2/show/NCT01061151
Feb 11th, 2022 - The incidence of mother-to-child transmission (MTCT) of HIV has decreased in recent years in the United States, Europe, and other resource-advantaged countries. Several factors have contributed to this decrease, including the administration of HAA...
https://clinicaltrials.gov/ct2/show/NCT04931641
Jan 21st, 2022 - Iron deficiency anemia (IDA) in childhood can impair growth and cognition, as well as reduce school performance. Furthermore, anemia frequently complicates pediatric HIV infection and predicts disease progression and mortality. However, there is n...
https://clinicaltrials.gov/ct2/show/NCT00000739
Nov 4th, 2021 - Prophylaxis for Pneumocystis carinii pneumonia ( PCP ) is recommended for all HIV-infected children considered to be at high risk. Approximately 15 percent of children are intolerant to trimethoprim / sulfamethoxazole, the first choice drug for PC...
News 5 results
https://reference.medscape.com/viewarticle/842465_6
Sep 11th, 2020 - The HHS guidelines for laboratory testing in patients with HIV receiving ART recommend a basic chemistry profile every 6 months. A random or fasting lipid profile and glucose profile are recommended every 12 months. A CD4 count is recommended ever...
https://www.mdedge.com/familymedicine/article/165686/hiv/fda-seeks-comments-pediatric-hiv-product-development
Infectious Disease Practitioner; Mark S. Lesney
May 14th, 2018 - The U. S.
https://www.mdedge.com/infectiousdisease/article/165686/hiv/fda-seeks-comments-pediatric-hiv-product-development
Mark S. Lesney
May 14th, 2018 - The U. S.
http://www.fda.gov/regulatory-information/search-fda-guidance-documents/pediatric-hiv-infection-drug-development-treatment
Docket Number: FDA-2018-D-1638 Issued by: Guidance Issuing Office Center for Drug Evaluation and Research Center for Biologics Evaluation and Research The purpose of this guidance is to provide general recommendations on the development of antiret...
https://www.mdedge.com/dermatology/article/7387/health-policy/ivig-reimbursement-cuts-threaten-patient-access
Alicia Ault
Physicians as well as patient and industry representatives say that a congressionally imposed reduction in Medicare reimbursement for intravenous immunoglobulinwhen combined with several other factorsis having a devastating impact on access to t.